Scholars Central

Conference abstract

Dendritic cell-based cancer immunotherapy

Authors: Shigetaka Shimodaira

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Despite the significant recent advances in the therapeutics for cancer, it still remains extremely difficult to treat advanced cancers with organ involvement and distant metastasis. A manufacturing technology for antigen-presenting cell (APC)-based immunotherapy is being developed, with active dendritic cell (DC), the most potent APCs of the immune system, being under investigation for therapeutic vaccination against cancer for strong induction of the T-cells against tumor antigens. The ex vivo technique is being developed for DC-based cancer vaccination, most of which is the preparation of autologous mature monocytederived DCs derived from apheresis of patientsâ?? blood. Cancer vaccine therapies are principally attributed to the presence of tumorassociated antigens. Wilms tumor 1 (WT1), an attractive target antigen widely expressed in every cancer, sarcoma and leukemia has been shown to the most potent cancer-associated antigens for immunotherapy. DC vaccine loaded with HLA class I/II-restricted WT1 peptides may be potentially strong therapeutic activity against cancers. DC-based immunotherapy targeting WT1 was indicated to be safe and feasible for the management of advanced cancers including pancreas, lung and ovary, exhibiting â??delayed separationâ?? curve in some patients. The vaccination would be feasible option even for patients with malignant brain tumor and acute leukemia after hematopoietic stem cell transplantation to control minimum residual disease. In future, the blockade of immune checkpoints in combination with DC-vaccination would be promising therapeutic strategies to activate therapeutic anti-tumor immunity for advanced cancers and hematological malignancies.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Blood Disorders & Transfusion.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood Disorders & Transfusion
  • SubjectHaematology
  • BylineArticles whose byline prints “Shigetaka Shimodaira”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels